Eupraxia Pharmaceuticals (EPRX) Capital Expenditures (2023 - 2026)
Eupraxia Pharmaceuticals (EPRX) reported Capital Expenditures of -$173,092 for Q2 2026, compared with -$166,225 a year earlier.
Powered by 
Analysis
Eupraxia Pharmaceuticals (EPRX) Capital Expenditures (2023 - 2026) Analysis & Trends
Over the twelve months ended Jun 30, 2026, Eupraxia Pharmaceuticals' Capital Expenditures came in at $424,171; for FY2025, it was $588,947, up 465.1% from FY2024.
- Capital Expenditures has a three-year compound annual growth rate of 35.7% (FY2022 to FY2025).
- By year, Capital Expenditures came in at $104,227 in FY2024 (+42.0%), $73,377 in FY2023 (-68.8%) and $235,550 in FY2022.
- Five-year quarterly Capital Expenditures spans a low of -$326,953 in Q1 2026 and a high of $984,593 in Q4 2025.
- Per Business Quant data, the three quarters before Q2 2026 came in at -$326,953 (Q1 2026), $984,593 (Q4 2025) and -$60,377 (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,348.13 Bn | 1,321.74 Bn | 20.46 Bn | 3.18 Bn |
| 2 | Johnson & Johnson | 675.90 Bn | 595.76 Bn | 17.30 Bn | 1.36 Bn |
| 3 | AbbVie | 519.45 Bn | 487.50 Bn | 13.12 Bn | 301.00 Mn |
| 4 | Merck | 364.95 Bn | 327.95 Bn | 13.19 Bn | 1.04 Bn |
| 5 | Novartis Ag | 311.58 Bn | 285.16 Bn | - | - |
| 6 | Astrazeneca | 289.34 Bn | 262.94 Bn | 13.26 Bn | -3.30 Bn |
| 7 | Amgen | 251.64 Bn | 203.30 Bn | 7.58 Bn | 587.00 Mn |
| 8 | Gilead Sciences | 212.05 Bn | 187.07 Bn | 6.73 Bn | 237.00 Mn |
| 9 | Pfizer | 167.35 Bn | 115.00 Bn | 12.56 Bn | 573.00 Mn |
| 10 | Eupraxia Pharmaceuticals | 304.87 Mn | -174.66 Mn | - | -133,957.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2026 | -133,957.00 |
| Jun 30, 2026 | -173,092.00 |
| Mar 31, 2026 | -326,953.00 |
| Dec 31, 2025 | 984,593.00 |
| Sep 30, 2025 | -60,377.00 |
| Jun 30, 2025 | -166,225.00 |
| Mar 31, 2025 | -169,044.00 |
| Dec 31, 2024 | 164,139.00 |
| Sep 30, 2024 | -42,275.00 |
| Jun 30, 2024 | -10,848.00 |
| Mar 31, 2024 | -6,789.00 |
| Dec 31, 2023 | 97,369.00 |
| Sep 30, 2023 | -9,602.00 |
| Jun 30, 2023 | -6,322.00 |
| Mar 31, 2023 | -8,068.00 |
API Access
Eupraxia Pharmaceuticals Capital Expenditures API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=capital-expenditures&ticker=EPRX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "capital-expenditures", "ticker": "EPRX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=capital-expenditures&ticker=EPRX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();